# Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

> **NCT04277637** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **BeOne Medicines** · enrollment: 437 (actual)

## Conditions studied

- Mature B-Cell Malignancies

## Interventions

- **DRUG:** Sonrotoclax
- **DRUG:** Zanubrutinib
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT04277637
- **Lead sponsor:** BeOne Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-24
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 437 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04277637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04277637, "Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04277637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*